REVIEW OF BIOLOGICAL THERAPY FOR ATOPIC DERMATITIS

Asli Ahmed Abdi*

ABSTRACT

Background: Atopic dermatitis, also known as ‘atopic eczema’, is considered to be common and recurrent skin disease which causes chronic inflammation prevalent at any age group in both adults and children in both the less- developed and the industrialized countries of the world. Objective: The aim of this systematic review was to derive authentic biological therapies for the accurate treatment of AD in current advanced medical era. Methods: We collected the clinical trials involved with the recent biologics for AD treatment through PRISMA exclusion criteria. Then we determined the safety and efficacy of these therapies by utilizing qualitative analysis and finally we determined risk of bias using Rev Man 5.4.1 tool for bias assessment. Results: The literature search yielded fifty studies for this review. Primarily all of the assessed interventions (molecular and biological treatments) showed significant superiority compared with placebo. Most of the biological agents showed significant improvement for participants with positive safety and efficacy levels except for Secukinumab and MOR106. When compared with placebo and other agents, biological agent’s dupilumab and ustekinumab are the best choices for attaining safe levels of treatment. Conclusion: Continual assessment of newly introduced treatments is crucial to find the most effective or personalized treatments for AD owing to its recurrent and heterogeneous nature.

Keywords: Atopic dermatitis, Atopic Eczema, Biological therapy, Biological drugs, Immunotherapy, Systematic Review.